看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -9.6x - -10.7x | -10.1x |
| Selected Fwd P/E Multiple | -1.2x - -1.3x | -1.3x |
| Fair Value | A$0.28 - A$0.31 | A$0.30 |
| Upside | -6.5% - 3.3% | -1.6% |
| Benchmarks | - | Full Ticker |
| BPH Global Ltd | - | ASX:BP8 |
| Immuron Limited | - | ASX:IMC |
| Alterity Therapeutics Limited | - | ASX:ATH |
| Prescient Therapeutics Limited | - | ASX:PTX |
| Dimerix Limited | - | ASX:DXB |
| Paradigm Biopharmaceuticals Limited | - | ASX:PAR |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| BP8 | IMC | ATH | PTX | DXB | PAR | |||
| ASX:BP8 | ASX:IMC | ASX:ATH | ASX:PTX | ASX:DXB | ASX:PAR | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 32.9% | -89.4% | -61.1% | 8.7% | -114.5% | 79.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -198871.9% | -750.6% | -8988.1% | -284.4% | -3571.4% | -125344.1% | ||
| Prior Fiscal Year | -1133569.9% | -209.8% | -352.5% | -288.5% | -37520.9% | NA | ||
| Latest Fiscal Year | -1799.3% | -141.5% | -475.8% | -221.9% | -2926.4% | NA | ||
| Latest Twelve Months | -947.8% | -112.4% | -531.3% | -234.0% | -3159.0% | -87172.0% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -1.7x | -1.4x | -2.1x | -4.2x | -8.1x | -4.9x | ||
| Price / LTM Sales | 11.3x | 2.4x | 12.5x | 10.9x | 284.4x | 7631.7x | ||
| LTM P/E Ratio | -1.2x | -2.1x | -2.4x | -4.7x | -9.0x | -8.8x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -9.0x | -2.4x | -1.2x | |||||
| Historical LTM P/E Ratio | -49.5x | -5.8x | -1.4x | |||||
| Selected P/E Multiple | -9.6x | -10.1x | -10.7x | |||||
| (x) LTM Net Income | (15) | (15) | (15) | |||||
| (=) Equity Value | 140 | 148 | 155 | |||||
| (/) Shares Outstanding | 389.4 | 389.4 | 389.4 | |||||
| Implied Value Range | 0.36 | 0.38 | 0.40 | |||||
| FX Rate: AUD/AUD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.36 | 0.38 | 0.40 | 0.30 | ||||
| Upside / (Downside) | 20.1% | 26.5% | 32.8% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BP8 | IMC | ATH | PTX | DXB | PAR | |
| Value of Common Equity | 2 | 15 | 47 | 32 | 204 | 117 | |
| (/) Shares Outstanding | 608.3 | 233.5 | 6,656.8 | 805.3 | 559.3 | 389.4 | |
| Implied Stock Price | 0.00 | 0.06 | 0.01 | 0.04 | 0.37 | 0.30 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.00 | 0.06 | 0.01 | 0.04 | 0.37 | 0.30 | |
| Trading Currency | AUD | AUD | AUD | AUD | AUD | AUD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |